We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer (CEASE)

This study has been terminated.
(Unable to recruit sufficient patients)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01351844
First Posted: May 11, 2011
Last Update Posted: August 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Victoria Shanmugam, George Washington University
  Purpose
Patients have been asked to participate in the CEASE study because their treating oncologist has recommended that they start an aromatase inhibitor medication. These medications are associated with joint complaints. The purpose of this study is to see whether a computer-based educational module is a feasible intervention to help address these symptoms. If the patients agree to participate, a research coordinator will test their grip strength and give them a computer log-on code. They will be shown how to log-on to complete the educational module and a few simple questionnaires. Patients have the option to do this from home if they wish. In 3 months time, the investigators will ask patients to return to the clinic and have another grip strength evaluation and complete some additional questionnaires. The computer module and the follow up visit will each take about 30 minutes of time.

Condition Intervention
Breast Cancer Arthralgia Behavioral: Education and exercise intervention Behavioral: Education and General Exercise

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

Resource links provided by NLM:


Further study details as provided by Victoria Shanmugam, George Washington University:

Primary Outcome Measures:
  • Feasibility [ Time Frame: 3 months ]
    This study is designed as a pilot study to assess feasibility of this educational intervention in a small population of only 40 patients. Patients will be given the option to complete the module from home. The primary endpoint will be patient completion of the educational module and follow-up questionnaires.


Secondary Outcome Measures:
  • Grip Strength [ Time Frame: 3 months ]
    The impact of the exercise education on symptoms will be assessed using grip strength evaluation with dynamometer at the baseline and three month follow-up visits, along with standardized pain and quality of life questionnaires completed at both time points.


Enrollment: 12
Study Start Date: May 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Education and exercise intervention
The "intervention" module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises.
Behavioral: Education and exercise intervention
An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
Placebo Comparator: Education and general exercise
The "control" module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises.
Behavioral: Education and General Exercise
A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post-menopausal stage I-III breast cancer patients
  • Starting or about to start aromatase inhibitor
  • English speaking with ability to read, write and use a computer to watch and listen to an educational module.
  • Able to give informed consent

Exclusion Criteria:

  • Aromatase inhibitor (AI) use for more than 6 months
  • Metastatic breast cancer
  • Non-English speaking, or unable to read, write or use a computer to watch and listen to an educational module.
  • Unable to give informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01351844


Locations
United States, District of Columbia
Victoria Shanmugam
Washington, D.C., District of Columbia, United States, 20037
Sponsors and Collaborators
George Washington University
Investigators
Principal Investigator: Victoria K Shanmugam, MD Georgetown University Hospital
  More Information

Responsible Party: Victoria Shanmugam, Associate Professor of Medicine, George Washington University
ClinicalTrials.gov Identifier: NCT01351844     History of Changes
Other Study ID Numbers: 2010-548
First Submitted: May 10, 2011
First Posted: May 11, 2011
Last Update Posted: August 30, 2017
Last Verified: August 2017

Keywords provided by Victoria Shanmugam, George Washington University:
Aromatase inhibitor
Arthralgia Syndrome
Exercise

Additional relevant MeSH terms:
Breast Neoplasms
Arthralgia
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Joint Diseases
Musculoskeletal Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms